Randomized clinical trial of autologous skin cell suspension combined with skin grafting for chronic wounds

Hu, Zhicheng; Chen, D.; Guo, Dong; Liang, Yueying; Zhang, J.; Zhu, Jiayuan; Tang, Bin

doi:10.1002/bjs.9688

Cited by 55 publications

(51 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Autologous skin cell suspension enables delivery of viable keratinocytes, fibroblasts, melanocytes and Langerhans cells harvested from a small STSG sample for application across the wound surface. In addition, basal layer cells, extracted from the basal lamina, are known to have stem cell‐like characteristics, and may be important contributors to the clinical benefit derived from the cell suspension.…”

Section: Discussionmentioning

confidence: 99%

“…Autologous skin cell suspension technology is frequently used for acute and chronic wounds as an adjunct to standard skin grafting procedures. The autologous skin cell suspension is produced quickly and is available immediately for wound application.…”

Section: Discussionmentioning

confidence: 99%

“…). A biopsy area of 1 cm 2 was required to treat a donor site of 80 cm 2 , to achieve a cellular spread rate of 1 : 80. Treated donor sites were covered with the non‐adherent hydrocolloid dressing (Urgotul ® ) and then wrapped with conventional gauze dressings.…”

Section: Methodsmentioning

confidence: 99%

“…Moreover, as the cell suspension contains viable melanocytes, it has been used on pigmentation lesions such as in vitiligo and congenital melanocytic naevus to improve repigmentation. Hu and colleagues recently reported in a randomized trial that the autologous skin cell suspension combined with a split‐thickness skin autograft improved chronic wound healing and long‐term aesthetic appearance. Similarly, Campanella and co‐workers reported comparative results of a silicone dressing and a monofilament polyamide woven dressing on paediatric donor sites treated with skin cells obtained by the ReCell ® system.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Randomized clinical trial of autologous skin cell suspension for accelerating re-epithelialization of split-thickness donor sites

Guo

Liu

et al. 2017

British Journal of Surgery

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Randomized clinical trial of autologous skin cell suspension for accelerating re-epithelialization of split-thickness donor sites

Guo

Liu

et al. 2017

British Journal of Surgery

Self Cite

View full text Add to dashboard Cite

show abstract

“…This may lead to an accelerated resurfacing phase and thus overall improved wound healing quality. For example, it could be demonstrated that the combination of keratinocytes with split‐skin grafts leads to an increased take rate in chronic wounds and less complications concerning wound healing . The use of cultured keratinocytes to support the healing process in complex wounds is also well‐documented .…”

Section: Discussionmentioning

confidence: 99%

Treatment of standardised wounds with pure epidermal micrografts generated with an automated device

Buehrer

Arkudas

Horch

2017

International Wound Journal

View full text Add to dashboard Cite

In this study, we analysed the effects of pure epidermal micrografts generated with an automated device in a standardised human wound model. Epidermal micrografts were harvested using an automated device. Micrografts were then transplanted onto split-skin donor sites. The target area was only partially covered with transplants to create an intra-individual control area. Wounds were evaluated by subjective assessment as well as measurements with combined laser and white light spectroscopy and cutometry. The epidermal graft sites remained completely stable, whereas control sites offered partially unstable and blistering areas. Statistically, no measurable difference in the speed of initial reepithelialisation could be shown. However, there was an increased pliability and softness of the treated areas that correlated with the subjective impression of both investigators and patients. There was a significantly higher relative haemoglobin concentration, measurable in treated and untreated areas at 4 weeks and 6 months. Cutometry showed no differences in skin properties between treated and untreated areas. This study shows an effect of epidermal micrografts in a standardised human wound model and supports the positive impact of keratinocytes on early wound healing as described in literature. Long-term effects of epidermal grafting deserve further studies.

show abstract

Hydrogel foam dressings with angiogenic and immunomodulatory factors from mesenchymal stem cells

Lan,

Fletcher,

Bender

et al. 2024

J Biomedical Materials Res

View full text Add to dashboard Cite

Stem cell therapy and skin substitutes address the stalled healing of chronic wounds in order to promote wound closure; however, the high cost and regulatory hurdles of these treatments limit patient access. A low‐cost method to induce bioactive healing has the potential to substantially improve patient care and prevent wound‐induced limb loss. A previous study reported that bioactive factors derived from apoptotic‐like mesenchymal stem cells (MSCs) demonstrated anti‐inflammatory and proangiogenic effects and improved ischemic muscle regeneration. In this work, these MSC‐derived bioactive factors were loaded into a hydrogel foam to harness immunomodulatory and angiogenic properties from MSC components to facilitate chronic wound healing without the high cost and translational challenges of cell therapies. After incorporation of bioactive factors, the hydrogel foam retained high absorbency, moisture retention, and target water vapor transmission rate. High loading efficiency was confirmed and release studies indicated that over 90% of loaded factors were released within 24 h. Ethylene oxide sterilization and 4‐week storage did not affect the bioactive factor release profile or physical properties of the hydrogel foam dressing. Bioactivity retention of the released factors was also confirmed for as‐sterilized, 4°C‐stored, and −20°C‐stored bioactive hydrogel foams as determined by relevant gene expression levels in treated pro‐inflammatory (M1) macrophages. These results support the use of the bioactive dressings as an off‐the‐shelf product. Overall, this work reports a new method to achieve a first‐line wound dressing with the potential to reduce persistent inflammation and promote angiogenesis in chronic wounds.

show abstract

Randomized clinical trial of autologous skin cell suspension combined with skin grafting for chronic wounds

Cited by 55 publications

References 22 publications

Randomized clinical trial of autologous skin cell suspension for accelerating re-epithelialization of split-thickness donor sites

Randomized clinical trial of autologous skin cell suspension for accelerating re-epithelialization of split-thickness donor sites

Treatment of standardised wounds with pure epidermal micrografts generated with an automated device

Hydrogel foam dressings with angiogenic and immunomodulatory factors from mesenchymal stem cells

Contact Info

Product

Resources

About